Roche launches blood test for can­cer de­tec­tion

BioSpectrum (Asia) - - World News -

Roche has launched a blood test that can iden­tify 70 of the most com­monly mu­tated genes in solid tu­mours, as the com­pany seeks to make more per­son­alised medicines. The test known as Foun­da­tionOne Liq­uid can iden­tify cir­cu­lat­ing tu­mour DNA in the blood of peo­ple liv­ing with can­cer and iden­tify the genes in­clud­ing mi­crosatel­lite in­sta­bil­ity, a ge­nomic sig­na­ture that can help in­form de­ci­sions about treat­ments based on can­cer im­munother­apy. Foun­da­tionOne Liq­uid com­ple­ments Roche’s Foun­da­tionOne CDx, a tis­sue­based ge­nomic pro­fil­ing test launched in the US ear­lier this year, as part of a port­fo­lio of ge­nomic tests. While Roche has used cir­cu­lat­ing tu­mour DNA re­leased by tu­mours into the blood­stream as they grow to test can­cers that doc­tors have al­ready spot­ted, the hope is that the tech­nol­ogy could be used to screen for can­cer be­fore symp­toms have ap­peared.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.